BioPharma Credit PLC - life sciences debt investment trust - Says had USD110 million investment in Epizyme Inc in form of senior secured loan. "The loan was made in four different tranches and each tranche had different prepayment economics," BioPharma adds. Ipsen on Friday completed acquisition of biopharmaceutical firm Epizyme. BioPharma says has received USD119 million, including USD9 million prepayment and make-whole fees. Realises internal rate of return of just over 15%.
Current stock price: USD0.97
12-month change: down 1.0%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Biopharma Cred. (BPCR)